AstraZeneca Reports Positive Lung Cancer Drug Trial Results
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
AstraZeneca (AZN) - Get Report reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months. AstraZeneca's Chief Medical Officer, says the phase three data suggests the drug has the potential to replace chemotherapy as the standard of care for patients with resistance to another drug for these health issues. The lung cancer drug received approval in Japan in March. Shares of AstraZeneca's moved slightly higher Tuesday.
